Two months ago, San Diego-based Otonomy made OTO-413 its lead development programme after OTO-313, a lipid-based formulation of gacyclidine, failed a phase 2 study looking at its efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback